Cristina Vilaplana

Cristina Vilaplana's work experience includes roles as a Researcher at the Germans Trias i Pujol Research Institute (IGTP), a Member of the Genetics and Microbiology Department at UAB - Universitat Autònoma de Barcelona, an Associate Professor and Lecturer at UAB, a Co-Founder Partner at MANREMYC, S.L., a Member of CB06/06/0031 Group at CIBER DE ENFERMEDADES RESPIRATORIAS (CIBERES), a Counsellor for the "Clinical TB Management Course" at Universitat Oberta de Catalunya, a Visiting Researcher at Imperial College London, and the Responsible of the Immunology Evaluation of the antiTB vaccine RUTI, Phase 1 Clinical Trial at Unitat de Tuberculosi Experimental.

Cristina Vilaplana has a diverse education history. In 1992-1999, they studied at the Universitat Autònoma de Barcelona, completing their MD in Medicine. From 2001-2004, they pursued a Clinical Microbiology Internal Residency (MIR) at the Hospital Universitari Germans i Pujol. In 2018-2019, they attended Esade, earning a Master's degree in Health/Health Care Administration/Management, specifically focused on the management of healthcare organizations (EMDOS). Additionally, they briefly attended Georgetown University McDonough School of Business in 2019, with no specific degree or field of study provided. Finally, Cristina has undertaken a PhD in Medicine at the Universitat Autònoma de Barcelona, although start and end years for this degree are not provided.